Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained its In-Line rating on Teladoc Health (TDOC) but has lowered its price target from $15 to $14.
April 26, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evercore ISI Group maintains an In-Line rating on Teladoc Health, with a reduced price target from $15 to $14.
The reduction in price target by Evercore ISI Group suggests a bearish outlook on Teladoc Health's short-term price potential, likely due to anticipated challenges or underperformance relative to market expectations. This adjustment in price target can influence investor sentiment negatively, potentially leading to a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100